NOVAVAX INC Federal State And Local Income Tax Expense Benefit Continuing Operations
NOVAVAX INC (NVAX) reported Federal State And Local Income Tax Expense Benefit Continuing Operations of $1.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations · last filed 2026-08-06
- NOVAVAX INC federal state and local income tax expense benefit continuing operations for the quarter ending 2026-06-30 was $1.70M, a 37.04% decline year-over-year.
- NOVAVAX INC federal state and local income tax expense benefit continuing operations for the quarter ending 2026-03-31 was $1.00M, a 16.67% decline year-over-year.
- NOVAVAX INC federal state and local income tax expense benefit continuing operations for the quarter ending 2025-09-30 was -$700.00K.
- NOVAVAX INC federal state and local income tax expense benefit continuing operations for the quarter ending 2025-06-30 was $2.70M, a 22.73% increase year-over-year.
| Period end | Federal State And Local Income Tax Expense Benefit Continuing Operations 3 month | Federal State And Local Income Tax Expense Benefit Continuing Operations 3 month as first filed | Federal State And Local Income Tax Expense Benefit Continuing Operations 6 month | Federal State And Local Income Tax Expense Benefit Continuing Operations 9 month | Federal State And Local Income Tax Expense Benefit Continuing Operations 9 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $1.70M 10-Q · filed 2026-08-06 | $900.00K 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $1.00M 10-Q · filed 2026-05-06 | ||||
| 2025-09-30 | -$700.00K 10-Q · filed 2025-11-06 | $2.00M derived: sum of 2 quarters · filed 2026-08-06 | $1.50M 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | $2.70M 10-Q · filed 2026-08-06 | $900.00K 10-Q · filed 2025-08-06 | $2.10M 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | $1.20M 10-Q · filed 2026-05-06 | $700.00K 10-Q · filed 2025-05-08 | |||
| 2024-09-30 | -$1.00M 10-Q · filed 2025-11-06 | -$1.30M 10-Q · filed 2024-11-12 | $1.20M derived: sum of 2 quarters · filed 2025-11-06 | $3.40M 10-Q · filed 2025-11-06 | $3.10M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $2.20M 10-Q · filed 2025-08-06 | $4.50M 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | $2.30M 10-Q · filed 2025-05-08 | ||||
| 2023-09-30 | -$700.00K 10-Q · filed 2024-11-12 | $300.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |